<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="33630"><DrugName>enzastaurin</DrugName><DrugNamesKey><Name id="43138694">Kinenza</Name><Name id="42798312">enzastaurin</Name><Name id="42857551">enzastaurin hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>LY-317615</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>317615.2HCl</Value></Name><Name><Value>enzastaurin</Value><Types><Type>INN</Type></Types></Name><Name><Value>PKC-beta inhibitor, Lilly</Value></Name><Name><Value>enzastaurin hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>DB-102</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Kinenza</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>365253-37-8</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>170364-57-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>359017-79-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17810">Eli Lilly &amp; Co</CompanyOriginator><CompaniesPrimary><Company id="17810">Eli Lilly &amp; Co</Company><Company id="1076271">Denovo Biopharma LLC</Company></CompaniesPrimary><CrossReferences><SourceEntity id="33630" type="Drug"><TargetEntity id="306147" type="siDrug">Enzastaurin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1076271" type="Company"><TargetEntity id="5037988341" type="organizationId">Denovo Biomarkers Inc</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"></TargetEntity><TargetEntity id="D005910" type="MeSH"></TargetEntity><TargetEntity id="-1503483999" type="omicsDisease"></TargetEntity><TargetEntity id="680" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1261" type="ciIndication"><TargetEntity id="10041056" type="MEDDRA"></TargetEntity><TargetEntity id="D055752" type="MeSH"></TargetEntity><TargetEntity id="70573" type="ORPHANET"></TargetEntity><TargetEntity id="-1257831198" type="omicsDisease"></TargetEntity><TargetEntity id="614" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1264" type="ciIndication"><TargetEntity id="C88.0" type="ICD10"></TargetEntity><TargetEntity id="273.3" type="ICD9"></TargetEntity><TargetEntity id="D008258" type="MeSH"></TargetEntity><TargetEntity id="-505069348" type="omicsDisease"></TargetEntity><TargetEntity id="1416" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"></TargetEntity><TargetEntity id="690" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1744" type="ciIndication"><TargetEntity id="C83.1" type="ICD10"></TargetEntity><TargetEntity id="10061275" type="MEDDRA"></TargetEntity><TargetEntity id="D020522" type="MeSH"></TargetEntity><TargetEntity id="52416" type="ORPHANET"></TargetEntity><TargetEntity id="-1332546842" type="omicsDisease"></TargetEntity><TargetEntity id="1384" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1745" type="ciIndication"><TargetEntity id="C82" type="ICD10"></TargetEntity><TargetEntity id="D008224" type="MeSH"></TargetEntity><TargetEntity id="-1402578461" type="omicsDisease"></TargetEntity><TargetEntity id="1742" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1749" type="ciIndication"><TargetEntity id="C83.3" type="ICD10"></TargetEntity><TargetEntity id="10012818" type="MEDDRA"></TargetEntity><TargetEntity id="D016403" type="MeSH"></TargetEntity><TargetEntity id="544" type="ORPHANET"></TargetEntity><TargetEntity id="-308083648" type="omicsDisease"></TargetEntity><TargetEntity id="1741" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1754" type="ciIndication"><TargetEntity id="D016410" type="MeSH"></TargetEntity><TargetEntity id="836" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2454" type="ciIndication"><TargetEntity id="10018336" type="MEDDRA"></TargetEntity><TargetEntity id="D005909" type="MeSH"></TargetEntity><TargetEntity id="360" type="ORPHANET"></TargetEntity><TargetEntity id="-1357419475" type="omicsDisease"></TargetEntity><TargetEntity id="678" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3083" type="ciIndication"><TargetEntity id="C48" type="ICD10"></TargetEntity><TargetEntity id="10061344" type="MEDDRA"></TargetEntity><TargetEntity id="D010534" type="MeSH"></TargetEntity><TargetEntity id="-745704479" type="omicsDisease"></TargetEntity><TargetEntity id="633" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="311" type="ciIndication"><TargetEntity id="10042971" type="MEDDRA"></TargetEntity><TargetEntity id="D016399" type="MeSH"></TargetEntity><TargetEntity id="-664594417" type="omicsDisease"></TargetEntity><TargetEntity id="704" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="316" type="ciIndication"><TargetEntity id="10003899" type="MEDDRA"></TargetEntity><TargetEntity id="-1829786210" type="omicsDisease"></TargetEntity><TargetEntity id="699" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"></TargetEntity><TargetEntity id="3229" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="54" type="ciIndication"><TargetEntity id="D002277" type="MeSH"></TargetEntity><TargetEntity id="-233893258" type="omicsDisease"></TargetEntity><TargetEntity id="665" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"></TargetEntity><TargetEntity id="D015179" type="MeSH"></TargetEntity><TargetEntity id="-1280257855" type="omicsDisease"></TargetEntity><TargetEntity id="594" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3934" type="Action"><TargetEntity id="3007" type="Mechanism">Protein Kinase PKC beta 2 Inhibitors</TargetEntity><TargetEntity id="1815" type="Mechanism">Protein Kinase PKC beta Inhibitors</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="PTGT-01620" type="ciTarget"><TargetEntity id="54919506155793" type="siTarget">Protein kinase C beta type</TargetEntity><TargetEntity id="2108" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1749">Diffuse large B-cell lymphoma</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="49">Breast tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1108">Glioma</Indication><Indication id="1261">Small-cell lung cancer</Indication><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="1264">Macroglobulinemia</Indication><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1744">Mantle cell lymphoma</Indication><Indication id="1745">Follicle center lymphoma</Indication><Indication id="1754">Cutaneous T-cell lymphoma</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="3083">Peritoneal tumor</Indication><Indication id="311">T-cell lymphoma</Indication><Indication id="316">B-cell lymphoma</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication><Indication id="4250">Metastatic renal cell carcinoma</Indication><Indication id="54">Carcinoma</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication><Indication id="799">Ovary tumor</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3934">Protein kinase C beta inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1589">Apoptosis stimulator</Action><Action id="61">Angiogenesis inhibitor</Action><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-30T09:50:02.000Z</LastModificationDate><ChangeDateLast>2019-06-19T00:00:00.000Z</ChangeDateLast><AddedDate>2001-04-04T15:49:10.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1076271" linkType="Company"&gt;Denovo Biopharma&lt;/ulink&gt;, following acquisition of the program from &lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly&lt;/ulink&gt;,  is developing enzastaurin (DB-102, Kinenza), an orally active serine/threonine kinase inhibitor which is believed to suppress signaling through the protein kinase C-beta (PKC-beta) and phosphoinositide 3-kinase (PI3K/AKT) pathways, as a personalized medicine for the potential treatment of diffuse large B-cell lymphoma (DLBCL). The drug is also being investigated for    the potential treatment of glioblastoma [&lt;ulink linkID="2105561" linkType="Reference"&gt;2105561&lt;/ulink&gt;], [&lt;ulink linkID="670272" linkType="Reference"&gt;670272&lt;/ulink&gt;], [&lt;ulink linkID="1594312" linkType="Reference"&gt;1594312&lt;/ulink&gt;], [&lt;ulink linkID="2105561" linkType="Reference"&gt;2105561&lt;/ulink&gt;].  In March 2018, a phase III trial  in DGM1-positive DLBCL patients was initiated in the US and China [&lt;ulink linkID="2018369" linkType="Reference"&gt;2018369&lt;/ulink&gt;]; in April 2018, patient dosing began [&lt;ulink linkID="2019241" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="2019129" linkType="Reference"&gt;2019129&lt;/ulink&gt;]; in June 2019, the pivotal phase III trial in first-line DLBCL was ongoing [&lt;ulink linkID="2165676" linkType="Reference"&gt;2165676&lt;/ulink&gt;]. In December 2018, a  phase II trial  of enzastaurin in combination with  &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt;, for glioblastoma was planned to initiate in June 2019 [&lt;ulink linkID="2105561" linkType="Reference"&gt;2105561&lt;/ulink&gt;]. In February 2018, Denovo was seeking to outlicense the drug to a partner in territories excluding the US and China [&lt;ulink linkID="2011358" linkType="Reference"&gt;2011358&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Denovo is also investigating &lt;ulink linkID="110839" linkType="Drug"&gt;enzastaurin&lt;/ulink&gt; for pulmonary artery hypertension (PAH) and emphysema [&lt;ulink linkID="2041016" linkType="Reference"&gt;2041016&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Eli Lilly  was developing enzastaurin (LY-317615; 317615.2HCI) for the potential treatment of cancer, primarily DLBCL [&lt;ulink linkID="670272" linkType="Reference"&gt;670272&lt;/ulink&gt;]. However, in May 2013,  Lilly reported that the phase III PRELUDE trial in patients with DLBCL in remission after first-line therapy had failed to meet its primary endpoint of significance in disease-free survival compared with placebo. At that time, the company stated that it was discontinuing development of the drug [&lt;ulink linkID="1418619" linkType="Reference"&gt;1418619&lt;/ulink&gt;]. In September 2014, Denovo acquired the late stage program for development as a personalized medicine [&lt;ulink linkID="1594312" linkType="Reference"&gt;1594312&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Enzastaurin was also in development for other hematological cancers. In May 2007, a phase II trial in follicular lymphoma began; in June 2012,  the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="1146924" linkType="Reference"&gt;1146924&lt;/ulink&gt;]. In November 2007, a phase II trial in T-cell and B-cell non-Hodgkins lymphomas was initiated; in June 2012, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="846863" linkType="Reference"&gt;846863&lt;/ulink&gt;]. A phase II trial in Waldenstrom's macroglobulinemia and multiple myeloma completed in August 2012 [&lt;ulink linkID="1069509" linkType="Reference"&gt;1069509&lt;/ulink&gt;]. A phase II trial involving patients with T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL), and indolent and aggressive B-cell lymphomas was ongoing as of June 2012 [&lt;ulink linkID="846863" linkType="Reference"&gt;846863&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug was also being developed for potential use in solid cancer indications. In March 2006, a phase III glioblastoma trial began [&lt;ulink linkID="654683" linkType="Reference"&gt;654683&lt;/ulink&gt;]. However, in December 2006, Lilly stopped enrollment in the trial after a data monitoring committee advised that the trial would not meet its primary endpoint [&lt;ulink linkID="752993" linkType="Reference"&gt;752993&lt;/ulink&gt;]. In November  2007, a phase II trial in glioblastoma with concomitant radiation was initiated. At that time, the study was expected to complete in March 2015 [&lt;ulink linkID="824510" linkType="Reference"&gt;824510&lt;/ulink&gt;]; in June 2011, data from the trial were reported  [&lt;ulink linkID="1194961" linkType="Reference"&gt;1194961&lt;/ulink&gt;]. In August 2005, phase II trials in colorectal cancer were initiated [&lt;ulink linkID="866836" linkType="Reference"&gt;866836&lt;/ulink&gt;]; in April 2011,    phase II trials in the maintenance setting were ongoing  [&lt;ulink linkID="1146811" linkType="Reference"&gt;1146811&lt;/ulink&gt;]. By November 2006, a phase II trial had been initiated in patients with ovarian cancer and primary peritoneal carcinoma [&lt;ulink linkID="769265" linkType="Reference"&gt;769265&lt;/ulink&gt;]; phase II  trials were ongoing in March 2011 [&lt;ulink linkID="779711" linkType="Reference"&gt;779711&lt;/ulink&gt;]. In March 2007, a phase II trial was initiated in breast cancer; in   October  2018, the trial was completed [&lt;ulink linkID="807940" linkType="Reference"&gt;807940&lt;/ulink&gt;].  In June 2008, a phase II trial in metastatic renal cell carcinoma was initiated; in December 2010, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="1146879" linkType="Reference"&gt;1146879&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Trials in other cancer indications were also previously carried out. A phase II trial in mantle cell lymphoma was initiated in March 2004 [&lt;ulink linkID="1146919" linkType="Reference"&gt;1146919&lt;/ulink&gt;]. By February 2005, phase II non-small-cell lung cancer (NSCLC) trials had begun [&lt;ulink linkID="583964" linkType="Reference"&gt;583964&lt;/ulink&gt;], and in December 2006, a phase II trial in metastases of NSCLC and small-cell lung cancer (SCLC) began [&lt;ulink linkID="1146873" linkType="Reference"&gt;1146873&lt;/ulink&gt;]. In January 2007, a phase II trial in prostate cancer was initiated [&lt;ulink linkID="782602" linkType="Reference"&gt;782602&lt;/ulink&gt;]. A phase II trial in chronic lymphocytic leukemia began in May 2007 [&lt;ulink linkID="801510" linkType="Reference"&gt;801510&lt;/ulink&gt;]. However no development has been reported for any of these indications.   &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;By March 2006, the FDA had granted the drug Orphan Drug status for glioblastoma [&lt;ulink linkID="654683" linkType="Reference"&gt;654683&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2009, the FDA granted the drug Orphan Status for DLBCL [&lt;ulink linkID="1010689" linkType="Reference"&gt;1010689&lt;/ulink&gt;]. In June 2011, a US filing for DLBCL was expected in late-2013 [&lt;ulink linkID="1204495" linkType="Reference"&gt;1204495&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In November 2005, the EU's Committee for Orphan Medicinal Products adopted a positive opinion on the granting of Orphan designation for the treatment of glioma [&lt;ulink linkID="634918" linkType="Reference"&gt;634918&lt;/ulink&gt;]; by January 2006, the EMEA had awarded the drug Orphan  status for glioma [&lt;ulink linkID="645104" linkType="Reference"&gt;645104&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2007, the EMEA granted Orphan Drug status for DLBCL [&lt;ulink linkID="777813" linkType="Reference"&gt;777813&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Glioblastoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2006, Lilly began a randomized, open-label phase III registration trial (&lt;ulink linkID="24582" linkType="Protocol"&gt;NCT00295815&lt;/ulink&gt;; STEERING) in relapsed glioblastoma multiforme (GBM), which was designed to compare oral enzastaurin to CCNU (lomustine).  The trial was designed to enroll 397 patients and complete in April 2012 [&lt;ulink linkID="654683" linkType="Reference"&gt;654683&lt;/ulink&gt;]. However, in December 2006, the company stopped enrollment after an external data monitoring committee advised that the trial would not meet its primary endpoint of improvement in progression-free survival (PFS). The company planned to review the data [&lt;ulink linkID="752993" linkType="Reference"&gt;752993&lt;/ulink&gt;]. In June 2008, data on deterioration of health related quality of life were presented at the 44th annual ASCO meeting in Chicago, IL. It was concluded that deterioration was similar for both drugs [&lt;ulink linkID="911771" linkType="Reference"&gt;911771&lt;/ulink&gt;]. In March 2011, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="1216234" linkType="Reference"&gt;1216234&lt;/ulink&gt;].   In December 2012, the trial was ongoing [&lt;ulink linkID="1346247" linkType="Reference"&gt;1346247&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2018, an interventional, randomized, parallel assignment, double-blind, placebo controlled, multicenter, phase IIb trial (&lt;ulink linkID="363554" linkType="Protocol"&gt;NCT03776071&lt;/ulink&gt;; DB102-201) of enzastaurin in combination with temozolomide was planned to initiate in June 2019	 in patients (expected n = 200) with newly diagnosed glioblastoma with or without DGM1. The primary endpoint was overall survival. At that time, the trial was expected to complete in December 2022 [&lt;ulink linkID="2105561" linkType="Reference"&gt;2105561&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2007, a non-randomized, open-label, single-group phase II trial (&lt;ulink linkID="25377" linkType="Protocol"&gt;NCT00586508&lt;/ulink&gt;; 11394; H6Q-MC-S033) began in the US to assess the safety and efficacy of enzastaurin in combination with &lt;ulink linkID="8047" linkType="Drug"&gt;bevacizumab&lt;/ulink&gt; in patients with recurrent malignant gliomas (n = 120). The primary endpoints were time-to-progression and safety. The study was due to complete in January 2011; however, in January 2011, the trial was still recruiting participants  [&lt;ulink linkID="1146900" linkType="Reference"&gt;1146900&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2009, data from a phase II trial of enzastaurin plus temozolomide in patients with GBM or gliosarcoma were presented at the 45th ASCO meeting in Orlando, FL. The primary endpoint was overall survival (OS). Patients received radiotherapy 60 Gy for 6 weeks and temozolomide at 75 mg/m2 daily during radiotherapy followed by 200 mg/m2, during a 28-day cycle, on days 1 to 5. Enzastaurin was administered at 250 mg/day adjuvantly during radiotherapy. By November 2008,  66 patients had been enrolled; at the time of analysis, 44 patients had progressed and 20 had died. Combination treatment was well tolerated [&lt;ulink linkID="1009590" linkType="Reference"&gt;1009590&lt;/ulink&gt;]. In June 2010, further data were presented at the 46th ASCO meeting in Chicago, IL. Progression-free survival (PFS) and OS results were comparable to that of a previous phase II trial of &lt;ulink linkID="11961" linkType="Drug"&gt;erlotinib&lt;/ulink&gt; plus temozolomide for newly diagnosed GBM or gliosarcoma and significantly better than a phase II study of temozolomide and cis-retinoic acid with radiation for supratentorial GBM and a phase II study of temozolomide and thalidomide for newly diagnosed GBM [&lt;ulink linkID="1104569" linkType="Reference"&gt;1104569&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November  2007, an open-label, uncontrolled, single-group phase II trial (&lt;ulink linkID="25378" linkType="Protocol"&gt;NCT00509821&lt;/ulink&gt;; 11491, H6Q-MC-S039) was initiated in patients  (n = 60) with newly diagnosed glioblastoma in Germany. At that time, the study was  expected  to complete in March 2015 [&lt;ulink linkID="824510" linkType="Reference"&gt;824510&lt;/ulink&gt;]. In June 2011,  data from this trial were presented at the 47th ASCO meeting in Chicago, IL. The primary endpoint, the 6-month PFS rate (51.8%), was not met.   Molecular analyses were ongoing to identify subgroups of patients to be enrolled in a controlled clinical trial [&lt;ulink linkID="1194961" linkType="Reference"&gt;1194961&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in October 2007, details of a phase I/II trial were presented at the International Glioma Research and Therapy Conference in Boston, MA. Patients with newly diagnosed chemotherapy-naive GBM patients  who had discontinued the use of enzyme-inducing antiepileptic drugs (n = 60) were to be enrolled. A 250 mg dose was chosen for the trial  with the endpoints including   determining PFS and further evaluating the safety profile  in combination with temozolomide and research therapy in newly diagnosed GBM. At that time, 3 of 60 patients had been enrolled, and pharmacogenetics studies were underway [&lt;ulink linkID="842114" linkType="Reference"&gt;842114&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2004, phase II data were presented at the 40th ASCO meeting in New Orleans, LA. Oral enzastaurin (500, 700 or 900 mg) was administered daily, on a 6-week cycle, to patients with recurrent high-grade glioma. Group A (n = 32) included patients also taking enzyme inducing antiepileptic drugs (EIAED) and group B did not. By June 2004, 40 from 47 patients were evaluable and 22 patients had received more than 1 cycle of treatment. Nine patients were stable on the treatment for more than 3 months and an objective response was seen in seven patients. Pharmacokinetic studies showed that the concentration of enzastaurin was 10-fold lower in patients in group B. The compound was well tolerated with only two cases of drug related toxicity of grade 3 severity or more (grade 3 and 4 thrombocytopenia). At that time, the trial was ongoing [&lt;ulink linkID="541026" linkType="reference"&gt;541026&lt;/ulink&gt;]. In May 2005, additional data were presented at the 41st ASCO meeting in Orlando, FL. A total of  92 patients had now been enrolled and treated with enzastaurin; 79 of these were evaluable for response. 1 patient achieved a complete response and 13 others had a partial response. 13 patients had stable disease for &amp;gt; 3 months treatment [&lt;ulink linkID="604029" linkType="Reference"&gt;604029&lt;/ulink&gt;], [&lt;ulink linkID="601762" linkType="Reference"&gt;601762&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2007, a pharmacokinetic phase I trial (&lt;ulink linkID="23788" linkType="Protocol"&gt;NCT00503724&lt;/ulink&gt;; CDR0000557572, PBTC-023) was initiated in young patients (estimated n = 20) with refractory primary brain tumors in the US. The patients were to receive enzastaurin once daily on days 1 to 28 and treatment was to be repeated every 28 days for a total of 13 courses in the absence of disease progression and unacceptable toxicity. The primary endpoint was maximum tolerated dose and a recommended phase II dose [&lt;ulink linkID="817318" linkType="Reference"&gt;817318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, a phase I trial of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed GBM or gliosarcoma was initiated. In October 2007,  data from this trial were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA. At that time, 12 patients had been enrolled. There was no DLT in the first six patients treated with 250 mg enzastaurin. At 500 mg, two of six patients experienced a DLT of grade 4 thrombocytopenia in the last week of radiotherapy. One patient recovered to Grade &amp;lt;1 toxicity within 28 days and was able to reinitiate adjuvant temozolomide and enzastaurin with dose reductions. The other patient recovered to Grade &amp;lt;1 toxicity after 28 days and did not restart treatment. The recommended phase II dose of enzastaurin concurrent with radiotherapy and temozolomide was 250 mg daily; this trial  opened in August 2007 [&lt;ulink linkID="840393" linkType="Reference"&gt;840393&lt;/ulink&gt;]. Further data presented at the meeting indicated that enzastaurin enhances the sensitivity of O6-MGMT+ glioblastomas to temozolomide [&lt;ulink linkID="845632" linkType="Reference"&gt;845632&lt;/ulink&gt;]. Similar data were presented at the 44th ASCO meeting in June 2008 [&lt;ulink linkID="824510" linkType="Reference"&gt;824510&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Diffuse large B-cell lymphoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 2014, Denovo planned to conduct genetic analysis to identify biomarkers that correlate with patients' responsiveness to treatment. The company was to  screen for appropriate patient subsets for enrollment in future clinical trials [&lt;ulink linkID="1594312" linkType="Reference"&gt;1594312&lt;/ulink&gt;]. In February 2017, an in-depth analysis of a failed  phase III study was conducted and it was  identified that a subset of patients showed improved survival based on DGM1, a novel biomarker, in both phase II and III studies over DGM1 negative patients.  At that time, based on the  encouraging  data, a randomized, double-blind, placebo-controlled, pivotal phase III study (&lt;ulink linkID="310951" linkType="Protocol"&gt;NCT03263026&lt;/ulink&gt;; DB102-02; ENGINE) was to be initiated in DGM1-positive, treatment-naive, high-risk DLBCL patients (expected n = 235) in the US and China. Subjects would receive R-CHOP plus enzastaurin or R-CHOP plus placebo. The primary endpoint would be overall survival at 3.5 years in patients with DGM1 [&lt;ulink linkID="2019129" linkType="Reference"&gt;2019129&lt;/ulink&gt;], [&lt;ulink linkID="1900956" linkType="Reference"&gt;1900956&lt;/ulink&gt;], [&lt;ulink linkID="2018369" linkType="Reference"&gt;2018369&lt;/ulink&gt;]. In October 2017, the FDA had granted  the IND  approval to proceed with the phase III trial in the US. By that  time, the CFDA had approved the IND for the trial in China [&lt;ulink linkID="1973734" linkType="Reference"&gt;1973734&lt;/ulink&gt;]. In March 2018, the trial was initiated. At that time, the trial was expected to complete in September 2021 [&lt;ulink linkID="2018369" linkType="Reference"&gt;2018369&lt;/ulink&gt;]. In April 2018, the first  patient was dosed. At that time, enrollment was ongoing in the US and China [&lt;ulink linkID="2019129" linkType="Reference"&gt;2019129&lt;/ulink&gt;]. In November 2018, retrospective clinical data about the new biomarker DGM1 were planned to be presented at ASH meeting in San Diego; at that time, the clinical data showed that overall survival (OS) of DGM1-positive  patients had significantly increased compared to that of DGM1-negative patients[&lt;ulink linkID="2097883" linkType="Reference"&gt;2097883&lt;/ulink&gt;]. In June 2019, the trial was ongoing [&lt;ulink linkID="2165676" linkType="Reference"&gt;2165676&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2006,  Eli Lilly initiated a global, randomized, placebo-controlled phase III trial (&lt;ulink linkID="24461" linkType="Protocol"&gt;NCT00332202&lt;/ulink&gt;; 9823; H6Q-MC-JCBJ; PRELUDE) to evaluate the drug as a maintenance therapy in patients with DLBCL in remission after first-line therapy (n = 459). Patients were to receive the drug for up to 3 years, and the primary endpoint of the study was disease-free survival. Biomarkers would also be monitored [&lt;ulink linkID="670272" linkType="Reference"&gt;670272&lt;/ulink&gt;]. At that time, the trial was expected to be complete by November 2013. By May 2010, the study was expected to complete in May 2017 [&lt;ulink linkID="680250" linkType="Reference"&gt;680250&lt;/ulink&gt;]. However, in May 2013,  Lilly reported that the trial had failed to meet its primary endpoint of significance in disease-free survival compared with placebo. Patients had received treatment until   disease progression, unacceptable adverse events or  completion of  three years of therapy. At that time, the company planned to present data from the trial at an upcoming scientific meeting [&lt;ulink linkID="1418619" linkType="Reference"&gt;1418619&lt;/ulink&gt;]. In December 2013, results were presented from the double-blinded study at the 55th ASH Meeting in New Orleans, LA. Patients (n = 758) received enzastaurin (500 mg daily) or placebo as maintenance therapy, for planned treatment duration of three years. The percentages of patients with disease free survival (primary endpoint) at months 24 and 48 months were 79 and 70%, respectively, in enzastaurin group and 75 and 71%, respectively, in placebo group. The overall survival  rates at months 24 and 48 were 87 and 81%, respectively, in enzastaurin group and 89 and 82%, respectively, in placebo group [&lt;ulink linkID="1503530" linkType="Reference"&gt;1503530&lt;/ulink&gt;]. In April 2015, correlative data from the trial were presented at the 106th AACR meeting in Philadelphia, PA. Differences in efficacy outcomes (disease free survival and overall survival) were not observed in the trial; however disease free survival and overall survival were numerically better in patients with low compared with high PKCB2 expression [&lt;ulink linkID="1650188" linkType="Reference"&gt;1650188&lt;/ulink&gt;].  In December 2018, further data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. When compared to DGM- patients receiving enzastaurin, DGM+ patients receiving enzastaurin had significantly improved OS (HR = 0.27; p = 0.002). Compared to DGM- patients, DGM+ patients receiving R-CHOP + enzastaurin had significantly improved OS (HR = 0.1; p = 0.005) [&lt;ulink linkID="2098374" linkType="Reference"&gt;2098374&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2007, a phase II, randomized, open-label, parallel-group study (&lt;ulink linkID="48535" linkType="Protocol"&gt;NCT00451178&lt;/ulink&gt;; 9824, H6Q-MC-S028) was initiated in the US, to evaluate the safety and efficacy of enzastaurin in combination with R-CHOP (&lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt;-cyclophosphamide, doxorubicin, vincristine and prednisolone) versus R-CHOP, in the first-line treatment of patients (estimated n = 100) with intermediate and high-risk DLBCL. The primary endpoint was progression-free survival (PFS). By July 2010, enrollment had been completed, and the study was expected to complete in September 2014 [&lt;ulink linkID="1202728" linkType="Reference"&gt;1202728&lt;/ulink&gt;]. In June 2011, data were presented at the 47th ASCO annual meeting in Chicago, IL. Patients received R-CHOP alone (n = 43) or R-CHOP plus enzastaurin (500 mg) on day 1 of every 21-day cycle, for 6 cycles (n = 57) or for up to 3 years (maintenance therapy). In the enzastaurin plus R-CHOP combination arm, one year PFS was 73%, compared with 52% for the R-CHOP only arm; the two-year overall survival rate was 75% and 68%, respectively. Complete responses were observed in 25% and 23.8% of enzastaurin plus R-CHOP  and R-CHOP patients, respectively; partial responses and stable disease were observed in 44.6% and 5.4%, and 57.7% and 2.4% of patients, respectively. Grade III/IV treatment-related adverse events observed included, neutropenia, leukopenia, febrile neutropenia, thrombocytopenia, anemia, fatigue, nausea, diarrhea and infection [&lt;ulink linkID="1196439" linkType="Reference"&gt;1196439&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, it was reported that the compound had entered phase II trials for DLBCL [&lt;ulink linkID="501382" linkType="reference"&gt;501382&lt;/ulink&gt;]. In December 2005, at the 47th Annual ASH meeting in Atlanta, GA, phase II results were released. The study enrolled 55 patients  with relapsed DLBCL, who had progressed following CHOP-based (or equivalent) chemotherapy. Patients received a dose of 525 mg  enzastaurin, amended to 500 mg po, until disease progression or unacceptable toxicity occurred. One cycle of therapy lasted for 28 days; 13 patients completed fewer than 1 therapy cycle,     noteworthy because enzastaurin must be administered for 14 days to achieve therapeutic levels. There were 11 dose omissions due to toxicities, of which 2 were possibly related to the study drug (fatigue and edema), and 12 patients were alive and free from progression at the end of 2 cycles. Two of these had elevated LDH levels at baseline, which normalized after enzastaurin therapy. A total of 9 patients had stable disease for at least 4 cycles, of whom 1 achieved a complete response; 2 of the patients had previously relapsed after  stem-cell therapy. Five patients with stable disease achieved a minor response. A total of 3 patients remained progression-free for at least 12, 17 and 32 cycles, respectively [&lt;ulink linkID="638623" linkType="Reference"&gt;638623&lt;/ulink&gt;]. In December 2018, further data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. Patients with high risk DLBCL+ receiving R-CHOP + enzastaurin versus high-risk DLBCL DGM1+ receiving R-CHOP alone,  biomarker analysis study showed significant improvement in overall survival (HR = 0.28; p = 0.018) [&lt;ulink linkID="2098374" linkType="Reference"&gt;2098374&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2017, a clinical trial application was filed by Denovo Biopharma to develop the product as a class 1 import chemical drug in China, presumably for DLBCL [&lt;ulink linkID="1889494" linkType="Reference"&gt;1889494&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cutaneous T-cell lymphoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In September 2008, an open-label, single-group assignment, phase II trial (&lt;ulink linkID="27660" linkType="Protocol"&gt;NCT00744991&lt;/ulink&gt;; 11496; H6Q-MC-JCCB) began in the US in patients (expected n = 25) with relapsed cutaneous T-cell lymphoma who had failed prior therapies. The primary endpoint was response rate. In March 2010, the trial completed [&lt;ulink linkID="1216138" linkType="Reference"&gt;1216138&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other hematological malignancies&lt;/subtitle&gt;A phase II trial in treatment-experienced patients with Waldenstrom's macroglobulinemia or multiple myeloma (n = 46) was initiated in July 2008. The open-label, multicenter trial (&lt;ulink linkID="25591" linkType="Protocol"&gt;NCT00718419&lt;/ulink&gt;) was to determine whether further study of single-agent enzastaurin was warranted in previously treated patients based on response and was due to complete in January 2011 [&lt;ulink linkID="1069509" linkType="Reference"&gt;1069509&lt;/ulink&gt;]. Preliminary data from the trial were presented at the 2009 American Society of Hematology Annual Meeting in December 2009. Of 29 patients, there were no complete responses, one partial response and seven minor responses, for a response rate of 27.6%. One patient had a drug-related grade 3 wound complication; there were no other drug-related grade 3 toxicities [&lt;ulink linkID="1059951" linkType="Reference"&gt;1059951&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2007, a multinational, non-randomized, open-label, parallel group phase II trial (&lt;ulink linkID="27661" linkType="Protocol"&gt;NCT00542919&lt;/ulink&gt;; 11503, H6Q-MC-S057) was initiated in patients (estimated n = 64) with T-cell lymphoma, indolent B-cell lymphoma or aggressive B-cell lymphoma. The patients were to receive 250 mg of oral enzastaurin  bid for 1 month starting on day 2 following a loading dose of 1125 mg on day 1. The primary endpoint was to evaluate the antitumor activity as measured by overall tumor response. The study was due to complete in February 2013. In June 2012, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="846863" linkType="Reference"&gt;846863&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, a multicenter, non-randomized, uncontrolled, open-label, single-group phase II trial (&lt;ulink linkID="43695" linkType="Protocol"&gt;NCT00475644&lt;/ulink&gt;; 8671l; H6Q-MC-S011) began in the US and Germany to assess the safety and efficacy of enzastaurin in patients with follicular lymphoma (n = 60). The primary endpoint was tumor response rate. The study was due to complete in December 2016. In May 2011,  the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="1146924" linkType="Reference"&gt;1146924&lt;/ulink&gt;]. In  December 2012, data were presented at the 54th ASH Meeting in Atlanta, GA. Patients received enzastaurin (500 mg po qd). Among the per-protocol patients (n = 53) and among biomarker population with PKC-beta2 (n = 24), the overall response rates (ORR) were 26 and 25%, respectively, and the median progressive-free survival (PFS) was 18.1 months. The confirmed complete response and partial response was achieved by 2 and 12 patients, respectively, and 13 had stable disease. Treatment was continued by seven patients. Enzastaurin was well tolerated [&lt;ulink linkID="1347857" linkType="Reference"&gt;1347857&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, a non-randomized, open-label, uncontrolled, single group, phase I trial (&lt;ulink linkID="40311" linkType="Protocol"&gt;NCT00452257&lt;/ulink&gt;; 10724; H6Q-MC-S022) was initiated in patients (estimated n = 30) with B-cell chronic lymphocytic leukemia (B-CLL) in the US.  The patients were to receive 1125 mg loading dose of enzastaurin followed by 500 mg of oral enzastaurin daily for up to 3 years or progressive disease. The primary endpoint was to characterize the inhibitory effects of enzastaurin  on  pGSK3 beta levels in B-CLL cells. At that time, the study was expected to be completed in December 2008. The trial completed in March 2009 [&lt;ulink linkID="801510" linkType="Reference"&gt;801510&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, a multicenter, randomized, open-label, active-controlled, single-group phase II trial (&lt;ulink linkID="27436" linkType="Protocol"&gt;NCT00088205&lt;/ulink&gt;; 8360; H6Q-MC-JCAO) began in Europe to assess the safety and efficacy of enzastaurin in patients with relapsed mantle cell lymphoma (n = 61). The primary endpoint was the rate of freedom from progression. The trial completed in May 2008 [&lt;ulink linkID="1146919" linkType="Reference"&gt;1146919&lt;/ulink&gt;]. In December 2006, data  were presented at the  48th ASH meeting in Orlando, FL. Patients had  received at least one prior chemotherapy regimen; patients received 500 mg enzastaurin once daily until disease progression or unacceptable toxicity occurred. The freedom-from-progression (FFP) rate was 36.7%, and median overall survival was 22 months; 22 patients were free from progression for at least three cycles of 28 days, while six patients were free from progression for at least six cycles. One patient, who had relapsed after high-dose chemotherapy and Ara-C, achieved a minor response of a 25 to 50% reduction in lesion size. The drug was well tolerated, with fatigue and diarrhea the most common adverse events [&lt;ulink linkID="749639" linkType="Reference"&gt;749639&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2009, clinical data were presented at the 51st ASH meeting in New Orleans, LA. Results from a phase I trial in multiple myeloma patients were presented. The recommended dose for phase II was determined as enzastaurin 250 mg po bid plus 1.3 mg/m2 bortezomib [&lt;ulink linkID="1059032" linkType="Reference"&gt;1059032&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Lung cancer&lt;/subtitle&gt;By February 2005, patient enrollment was ongoing for a US phase II trial in patients with advanced or metastatic NSCLC [&lt;ulink linkID="583964" linkType="Reference"&gt;583964&lt;/ulink&gt;]. In October 2008, enrollment in the multicenter, non-randomized, open-label study  was expected to be completed in December 2008. Patients were to receive 500 mg of enzastaurin in combination with 150 mg of &lt;ulink linkID="11961" linkType="Drug"&gt;erlotinib&lt;/ulink&gt; as a second line  or beyond therapy after progression [&lt;ulink linkID="951619" linkType="Reference"&gt;951619&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, a randomized, placebo-controlled, double-blind phase IIb chemoprevention trial (&lt;ulink linkID="27442" linkType="Protocol"&gt;NCT00414960&lt;/ulink&gt;) of enzastaurin was initiated in former smokers. Patients (estimated n = 39) 45 years of age or older, were randomized to receive 6 months treatment with either enzastaurin (500 mg qd, po) or placebo [&lt;ulink linkID="1268114" linkType="Reference"&gt;1268114&lt;/ulink&gt;]. In June 2011, data were presented at the 47th ASCO meeting in Chicago, IL. The percentage of cells positively labelled with KI-67 (KI-67 LI), a marker of cellular proliferation, was decreased from baseline to 6 months of therapy with either enzastaurin or placebo in 9 of the 32 patients with pre- and post-treatment bronchial samples (greatest mean change = - 27.7%). KI-67 LI was decreased in five of the patients with meta/dysplastic lesions (greatest mean change = - 19.2%) [&lt;ulink linkID="1194923" linkType="Reference"&gt;1194923&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, phase II  data were presented at the 18th EORTC-NCI-AACR meeting in Prague, Czech Republic, in patients with NSCLC. Patients received oral enzastaurin 500 mg once daily, for six cycles of 28 days. PFS was observed in 10.4% of patients (n = 53) at 6 months, although no objective tumor responses were seen. The drug was well tolerated, with fatigue being the most commonly reported toxicity. Long-term disease stabilization in three patients, who had progressed after one of two prior therapies, suggested enzastaurin may have activity in NSCLC [&lt;ulink linkID="741522" linkType="Reference"&gt;741522&lt;/ulink&gt;]. In June 2007, final data from the trial were presented at the 43rd ASCO meeting in Chicago, IL. The median progression free survival  was 1.9 months and the progression free survival rate at 6 months was  14%. The median overall survival was found to be 9.9 months. No complete or partial responses were observed, but 19 patients achieved stable disease. The most common adverse event was fatigue, but this was not observed in individuals who had stable disease [&lt;ulink linkID="801152" linkType="Reference"&gt;801152&lt;/ulink&gt;], [&lt;ulink linkID="797727" linkType="Reference"&gt;797727&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastases&lt;/subtitle&gt;In December 2006, a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II trial (&lt;ulink linkID="27560" linkType="Protocol"&gt;NCT00415363&lt;/ulink&gt;; 10710; H6Q-MC-S020; MENZA) began in Europe to assess the safety and efficacy of enzastaurin as maintenance therapy in patients with brain metastases of NSCLC and SCLC (n = 108), following whole brain radiation. The primary endpoint was time to worsening of brain metastases. The study completed in January 2011 [&lt;ulink linkID="1146873" linkType="Reference"&gt;1146873&lt;/ulink&gt;]. In September 2011, data were presented at the European Multidisciplinary Cancer Congress in Stockholm, Sweden. The median time-to-progression of brain metastases was 6.9 and 4.9 months, respectively for enzastaurin and placebo. Enzastaurin-treated patients achieved a median overall survival and median progression-free survival of 3.8 and 2.2 months, respectively compared with 5.1 and 2 months, respectively for placebo. The proportion of enzastaurin patients with partial response, stable disease and progressive disease for brain metastases was 4, 15 and 6 patients, respectively compared with 2, 22 and 8 patients, respectively for placebo. No complete responses (CR) were observed with enzastaurin therapy; however, one patient in the group showed CR [&lt;ulink linkID="1223994" linkType="Reference"&gt;1223994&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In June 2007, a US randomized, double blind, parallel group phase II study (&lt;ulink linkID="40303" linkType="Protocol"&gt;NCT00466440&lt;/ulink&gt;; 11311; H6Q-MC-S032) was initiated in patients (estimated n = 96) with hormone refractory prostate cancer. Patients were to receive placebo or enzastaurin in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; and prednisone. The primary endpoint was  the response rate of enzastaurin given with chemotherapy in  patients that had taken enzastaurin for a maximum of 3 years. The study completed in November  2010 [&lt;ulink linkID="807789" linkType="Reference"&gt;807789&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2007, a non-randomized, open-label, uncontrolled, parallel assignment phase II trial (&lt;ulink linkID="27558" linkType="Protocol"&gt;NCT00428714&lt;/ulink&gt;; 10737; H6Q-MC-S024) was initiated in patients (estimated n = 86) with prostate cancer in the US. The primary endpoint was to determine the response rates of enzastaurin in two cohorts of prostate cancer patients:  asymptomatic patients with androgen-independent PSA-progressive disease with or without clinical or radiographic evidence of metastatic disease (cohort 1), and patients with androgen-independent metastatic prostate cancer with rising PSA, and disease progression following one prior docetaxel-based regimen (cohort 2). The study was expected to enroll 72 patients and complete in September 2010 [&lt;ulink linkID="782602" linkType="Reference"&gt;782602&lt;/ulink&gt;]. Initial data were published in April 2010. One complete response was observed in cohort 1, with limited activity in the majority of patients. In cohort 2, no objective responses were seen and the median progression-free survival (11 weeks) did not differ from the historical control [&lt;ulink linkID="1196534" linkType="Reference"&gt;1196534&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In February 2008, a multinational, randomized, double-blind, placebo-controlled, parallel-group phase II trial (&lt;ulink linkID="27659" linkType="Protocol"&gt;NCT00612586&lt;/ulink&gt;; 10534; H6Q-MC-S064) began to assess the safety and efficacy of enzastaurin in combination with 5-fluorouracil/leucovorin plus &lt;ulink linkID="8047" linkType="Drug"&gt;bevacizumab&lt;/ulink&gt; as a maintenance regimen in patients with colorectal cancer (n = 150). The primary endpoint was PFS. The study was due to complete in March 2011. In April 2011, the trial was ongoing, but was no longer recruiting participants  [&lt;ulink linkID="1146811" linkType="Reference"&gt;1146811&lt;/ulink&gt;]. In June 2011, data were presented at the 47th ASCO meeting in Chicago, IL. Patients (n = 117) received placebo or enzastaurin 1125 mg/day po tid (125-mg tablets) on day 1 of cycle 1 (loading dose) and 500 mg/day bid for subsequent doses alone or in combination with leucovorin 400 mg/m2 iv infusion first plus 400 mg/m2 5-FU bolus followed by 2400 mg/m2 iv infusion over 46 h and bevacizumab (45 mg/kg iv infusion). In the enzastaurin and placebo arms, the median progression-free survival (PFS) from randomization (primary endpoint) was 5.8 and 8.1 months, respectively and the median PFS from start of first-line therapy (secondary endpoint) was 8.9 and 11.3 months, respectively [&lt;ulink linkID="1196429" linkType="Reference"&gt;1196429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, a randomized, open-label, uncontrolled, parallel-group phase II trial (&lt;ulink linkID="27562" linkType="Protocol"&gt;NCT00437268&lt;/ulink&gt;; 10538, H6Q-MC-S018) was initiated in patients (estimated n = 115) with recurrent colorectal cancer in the US. The patients were to receive 1125 mg loading dose of enzastaurin followed by 500 mg orally, daily on 21 day cycles in combination with iv &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; and &lt;ulink linkID="10388" linkType="Drug"&gt;cetuximab&lt;/ulink&gt; or iv irinotecan and cetuximab alone. The primary endpoint was progression free survival. At that time, the study was expected to complete in September 2009. The trial  completed in May 2009 [&lt;ulink linkID="866843" linkType="Reference"&gt;866843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2005, a non-randomized, open label, uncontrolled, single-group phase II trial (&lt;ulink linkID="25288" linkType="Protocol"&gt;NCT00192114&lt;/ulink&gt;; 9098, H6Q-MC-JCAR) was initiated in patients (estimated n = 45) with metastatic colorectal cancer in Denmark and Sweden. The patients were to receive enzastaurin daily. The primary endpoint was progression free survival. At that time, the study was scheduled to complete in March 2008 and by December 2007, the trial was no longer recruiting patients [&lt;ulink linkID="866836" linkType="Reference"&gt;866836&lt;/ulink&gt;]. Data from this study were presented at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland in October 2008. There were no clinical responses, although 12 of the 28 patients enrolled (43%) achieved stable disease. Overall survival was censored at 82%. The survival rate at 20 months was 77% and median PFS was 2 months [&lt;ulink linkID="952303" linkType="Reference"&gt;952303&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;In June 2008, data from a phase II breast cancer trial were presented at the 44th annual ASCO meeting in Chicago, IL. The trial failed its primary endpoint with no partial or complete responses  and no stable disease lasting 6 months.  At that time, trials of the drug in breast cancer  patients in combination with other therapies were ongoing [&lt;ulink linkID="913446" linkType="Reference"&gt;913446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, a randomized, double-blind, placebo-controlled, parallel group phase II trial (&lt;ulink linkID="27269" linkType="Protocol"&gt;NCT00451555&lt;/ulink&gt;; 10736; H6Q-MC-S023) was initiated in patients (estimated n = 132) with locally advanced or metastatic breast cancer in Europe. The patients were to receive fulvestrant plus enzastaurin or fulvestrant plus placebo. The primary endpoint was clinical benefit rate. At that time the study was expected to complete in October 2010. In  April 2011, the trial was ongoing, but was no longer recruiting participants. In August 2017, the trial was ongoing and was expected to complete in December 2018. In October 2018, the trial was completed   [&lt;ulink linkID="807940" linkType="Reference"&gt;807940&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ovarian cancer&lt;/subtitle&gt;In January 2007, a non-randomized, open-label, active-control, phase II trial (&lt;ulink linkID="25510" linkType="Protocol"&gt;NCT00420381&lt;/ulink&gt;, 10738, H6Q-MC-S025) was initiated in patients (estimated n = 50) with recurrent or persistent ovarian cancer or primary peritoneal cancer in the US. The primary endpoint was frequency of patients that had progression-free disease for at least 6 months or had an objective tumor response. At that time, the study was expected to complete in September 2010. In  March  2011, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="779711" linkType="Reference"&gt;779711&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase II trial (&lt;ulink linkID="35989" linkType="Protocol"&gt;NCT00391118&lt;/ulink&gt;; 10708; H6Q-MC-S019) began in Europe to assess the safety and efficacy of enzastaurin in combination with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; for the first-line and maintenance treatment of patients with advanced ovarian cancer (n = 149). The primary endpoint was PFS. The study was due to complete in July 2012   [&lt;ulink linkID="1146798" linkType="Reference"&gt;1146798&lt;/ulink&gt;].  In June 2011, data from the trial were presented at the 47th ASCO meeting in Chicago, IL.  Median progression-free survival  in the enzastaurin/carboplatin/paclitaxel group (n = 69) was 18.9 months compared with 15.2 months in the  carboplatin/paclitaxel group (n = 73). The major  hematological adverse event of  grade 4 severity was neutropenia, which was reported by 42 and 32% of patients in the triple and dual therapy arm, respectively [&lt;ulink linkID="1196013" linkType="Reference"&gt;1196013&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, an open-label, phase II trial (&lt;ulink linkID="35672" linkType="Protocol"&gt;NCT00407758&lt;/ulink&gt;; CDR0000517318; GOG-0170J; LILLY-H6Q-MC-S025) was initiated in patients (estimated n = 68) with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma in the US. The patients were to receive oral  enzastaurin  three times on day 1 of the study and once-daily  thereafter. The primary endpoint was  frequency of patients with 6-month PFS or objective tumor response and secondary endpoints included duration of PFS and overall survival. The study was still recruiting in February 2007 [&lt;ulink linkID="769265" linkType="Reference"&gt;769265&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Renal cell carcinoma&lt;/subtitle&gt;In June 2008, a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase II trial (&lt;ulink linkID="43862" linkType="Protocol"&gt;NCT00709995&lt;/ulink&gt;; 11531; H6Q-MC-S061) began in Europe to assess the safety and efficacy of enzastaurin in combination with &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt; compared with sunitinib alone in patients with metastatic renal cell carcinoma (n = 122). The primary endpoint was PFS. The study was due to complete in September 2011. In December 2010, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="1146879" linkType="Reference"&gt;1146879&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;In November 2012, data from a clinical study were presented at the 24th EORTC-NCI-AACR symposium in Dublin, Ireland. Patients (n = 23) received a single dose of enzastaurin (500 mg qd). In cancer patients with mild, moderate, and severe hepatic dysfunction (HD), with increasing severity of HD, the mean exposure of enzastaurin and its major active metabolite was reduced. Enzastaurin was well tolerated [&lt;ulink linkID="1336618" linkType="Reference"&gt;1336618&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;In October 2008,   data from a non-randomized, open-label, single-center phase I study were presented at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland. A total of 16 patients received 150 mg of erlotinib on an empty stomach plus 250 or 375 mg of enzastaurin with food for 28 days. A partial response was seen in one patient and 3 had stable disease for at least 7 months, including one patient showing a 27% reduction in tumor size. The recommended phase II dose for enzastaurin was 500 mg  and 150 mg for erlotinib.  At that time, pharmacokinetic analysis was ongoing [&lt;ulink linkID="951619" linkType="Reference"&gt;951619&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in October 2008,  data from a Japanese phase I trial were presented at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland, showing the drug was well tolerated up to 500 mg/d in patients with advanced cancer. A total of 28 patients  received enzastaurin starting with 250 mg once daily until disease progression or unacceptable toxicity. None of the patients  achieved a complete or partial response, however, one mesothelioma patient showed radiographical improvement. The recommended dose for  phase II trials was 500 mg dose for a 28-day cycle [&lt;ulink linkID="952171" linkType="Reference"&gt;952171&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, a non-randomized, open-label, phase I trial (&lt;ulink linkID="40372" linkType="Protocol"&gt;NCT00550927&lt;/ulink&gt;; CDR0000571514, LILLY-H6Q-MC-S029, JHOC-J0688) was initiated in patients (estimated n = 42) with locally advanced or metastatic cancer in the US. The patients were to receive oral enzastaurin qd, bid or tid on days 1 to 21 or days 1 to 28 and iv &lt;ulink linkID="8047" linkType="Drug"&gt;bevacizumab&lt;/ulink&gt; over 30 to 90 min on day 1 or days 1 and 15. The course was to be repeated every 21 or 28 days in the absence of disease progression or unacceptable toxicity. The primary endpoint was safety. In October 2007, recruitment was ongoing [&lt;ulink linkID="851565" linkType="Reference"&gt;851565&lt;/ulink&gt;]. In June 2008, clinical data were presented at the 44th annual ASCO meeting in Chicago, IL. The combination was clinically active with 6 patients with partial responses, 11 with stable disease and 10 with progressive disease, out of 27 patients evaluable. At that time, enrollment was ongoing [&lt;ulink linkID="911485" linkType="Reference"&gt;911485&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2006, phase I, dose escalation  data on enzastaurin in combination other chemotherapeutics were presented at the 42nd ASCO meeting in Atlanta, GA. In a dose escalation trial patients (n = 33) received an enzastaurin loading dose and then enzastaurin orally (350 mg qd to 500 mg bid) on days 1 to 21, combined with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; (1000 or 1250 mg/m2) on days 1 and 8 and &lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt; (60 or 75 mg/m2) on day 1 on a 21 day cycle. The recommended phase II dose was established as 500 mg enzastaurin, twice-daily, 1250 mg/m2 gemcitabine and 75 mg/m2 cisplatin. Of 24 patients evaluable for efficacy, 3 had a partial response and 13 had stable disease for 2 or more months. Grade I and II toxicities were higher in the twice-daily dosing regimens [&lt;ulink linkID="669114" linkType="Reference"&gt;669114&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Pharmacokinetic data for enzastaurin in combination with &lt;ulink linkID="3536" linkType="Drug"&gt;pemetrexed&lt;/ulink&gt; were also presented at the 42nd ASCO meeting. Following a loading dose of enzastaurin (1200 mg), patients (n = 21) received pemetrexed (500 mg/m2) on day 1 of the cycle and enzastaurin (500 mg bid po) for the 21-day cycle. Enzastaurin pharmacokinetic parameters did not change in the presence of pemetrexed and pemetrexed was not affected by enzastaurin; the average steady-state concentration of enzastaurin was 1270 nM alone and 1130 nM with pemetrexed [&lt;ulink linkID="669115" linkType="Reference"&gt;669115&lt;/ulink&gt;]. In May 2009, further data were presented at the 45th ASCO meeting in Orlando, FL. A partial response was seen in one subject and six achieved stable disease [&lt;ulink linkID="1008715" linkType="Reference"&gt;1008715&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2004, data from a phase I combination trial of enzastaurin and &lt;ulink linkID="12205" linkType="Drug"&gt;capecitabine&lt;/ulink&gt;  were presented at the 16th EORTC-NCI-AACR meeting in Geneva, Switzerland. This phase I study was designed to evaluate the safety and PK behavior of enzastaurin (350 to 700 mg/day po days 1 to 21) and capecitabine (750 to 1000 mg/m2/day po bid days 1 to 14) administered in 3-week courses to patients with advanced cancer. By that time, 15 patients had received 47 courses; 14 were evaluable for toxicity. DLT was experienced by two of six patients (grade 3 QTC prolongation and grade 3 chest pain due to 5-fluorouracil (FU)-induced coronary vasospasm) at the 350/1000 dose mg/m2/day level. No other significant QTC prolongation was observed. The protocol was amended to expand that cohort since the idiosyncratic reaction to FU might not represent a true dose-limiting event. Other non-hematological toxicity was mild and included HFS, diarrhea, and nausea. No visual toxicity or grade 3 to 4 hematological toxicity was seen. Of 13 patients evaluable for response, 1 patient (pancreatic cancer) maintained stable disease for 9 courses, 3 patients (colon, lung, sarcoma) have maintained stable disease for 4 courses. One patient discontinued after cycle 2 for toxicity (QTC prolongation). PK analysis was pending in addition to biological analysis of ex vivo whole blood stimulation. This combination schedule was well tolerated. Accrual was ongoing to establish the MTD of the combination, after which phase II studies were planned [&lt;ulink linkID="562834" linkType="Reference"&gt;562834&lt;/ulink&gt;]. In June 2006, phase I, dose escalation clinical data on enzastaurin in combination with &lt;ulink linkID="12205" linkType="Drug"&gt;capecitabine&lt;/ulink&gt; were presented at the 42nd ASCO meeting in Atlanta, GA. Following a loading dose of enzastaurin, patients (n = 27) received enzastaurin 350 to 525 mg qd for 21 days and capecitabine 750 to 1000 mg/m2 bid for days 1 to 14 of a 21-day cycle; a median number of 3 cycles were received. The recommended phase II dose was established as 500 mg enzastaurin plus 1000 mg/m2 capecitabine. The combination was well tolerated with common adverse effects including nausea (48%), fatigue (33%) and diarrhea (26%). A best response of stable disease was achieved in 10 patients [&lt;ulink linkID="669115" linkType="Reference"&gt;669115&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2002, clinical data were presented at the 38th ASCO meeting in Orlando, FL. Enzastaurin was administered orally at escalating dose levels (20 to 350 mg) to patients with solid tumors. The most common adverse event was grade I fatigue, and one patient at the 160 mg dose had grade 2 arthralgia, resulting in dose reduction.The half-life of enzastaurin ranged from 9 to 25 h and the drug did not accumulate to a significant degree. Four out of 27 patients had stable disease after more than four cycles of treatment [&lt;ulink linkID="452198" linkType="reference"&gt;452198&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2001, initial clinical data were presented at the AACR-NCI-EORTC meeting, Miami Beach, FL. Data from the first nine patients showed no drug-related or dose-limiting toxicities, with doses up to 80 mg/day [&lt;ulink linkID="429846" linkType="reference"&gt;429846&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2018, preclinical data were planned to present at the ASH conference in San Diego. The preclinical data showed that the drug, in combination with &lt;ulink linkID="55237" linkType="Drug"&gt;ibrutinib&lt;/ulink&gt; led to synergistic antitumor activity in ABC and GCB DLBCL cell lines and also synergistically inhibited tumor cell migration and invasion as well as key related signal transduction pathways [&lt;ulink linkID="2097883" linkType="Reference"&gt;2097883&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, preclinical data were presented at the 48th ASCO meeting in Chicago, IL. In activated B-cell and germinal center DLBCL cells, its primary metabolite, LY-326020 inhibited PKC and PI3K-AKT-TOR pathway more potently than enzastaurin. Enzastaurin and LY-326020 reduced the phosphorylation of numerous proteins in the PI3K-AKT-TOR pathway in both sensitive and resistant cells in a dose- and time-dependent manner [&lt;ulink linkID="1299340" linkType="Reference"&gt;1299340&lt;/ulink&gt;]. In December 2012, further data were presented at the 54th ASH Meeting in Atlanta, GA. Apoptosis in both germinal center and activated B-cell models was robustly induced by enzastaurin by blocking P13K/AKT pathway. Additionally, LY-326020.HCl more potently induced apoptosis in the same cell lines [&lt;ulink linkID="1346247" linkType="Reference"&gt;1346247&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the 103rd AACR meeting in Chicago, IL. In DLBCL cells, both enzastaurin and its primary metabolite, LSN-492403, induced apoptosis. The signaling through PI3K/AKT/TOR pathway was potently blocked by LSN-492403.  In the DLBCL sensitive cell lines, the phosphorylation of factor 4E binding protein 1 was most profoundly decreased. DLBCL xenograft model (OCI-Ly19) treated with enzastaurin showed reduced tumor volume compared with vehicle-treated animal [&lt;ulink linkID="1275298" linkType="Reference"&gt;1275298&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, preclinical data were presented at the 50th ASH meeting in San Francisco, CA, establishing a role for b-catenin accumulation in enzastaurin activity against multiple myeloma [&lt;ulink linkID="968129" linkType="Reference"&gt;968129&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data were presented at the 99th AACR annual meeting in San Diego, CA, showing that enzastaurin enhanced the efficacy of &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt; in multiple glioblastoma cell lines, through the  inhibition of p90 ribosomal S6 kinase activity, which sensitized glioblastoma cells to temozolomide-induced apoptosis [&lt;ulink linkID="895488" linkType="Reference"&gt;895488&lt;/ulink&gt;]. Enzastaurin was also shown to enhance the efficacy of &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt;, &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt;, &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; and &lt;ulink linkID="12205" linkType="Drug"&gt;capecitabine&lt;/ulink&gt; in xenograft mouse models [&lt;ulink linkID="895469" linkType="Reference"&gt;895469&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006,  data were presented at the 48th ASH meeting in Orlando, FL. Enzastaurin was found to significantly    induce dose-dependent apoptosis and to inhibit proliferation of Waldenstroem's macroglobulinemia (WM) cell lines both in vivo and in vitro. Enzastaurin was also found to act synergistically in combination with bortezomib and fludarabine [&lt;ulink linkID="750218" linkType="Reference"&gt;750218&lt;/ulink&gt;]. Further data were presented at the meeting which showed  that enzastaurin inhibited  proliferation and survival of MM cell lines isolated from multidrug- resistant patients. Synergistic cytotoxicity was observed when combined with bortezomib. The drug was found to inhibit MM cell adhesion, as well as VEGF- and IGF-1-triggered MM cell migration. The study also showed that tumor growth, survival, and angiogenesis were abrogated by enzastaurin in a xenograft model of human MM [&lt;ulink linkID="750787" linkType="Reference"&gt;750787&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2006,  data were presented  at the 97th AACR meeting in Washington DC. Enzastaurin (100 mg/kg bid for 7 days) suppressed tumor growth in malignant glioma U87MG and HCT116 xenograft models [&lt;ulink linkID="661763" linkType="Reference"&gt;661763&lt;/ulink&gt;]. Further data were presented at the meeting. In HCT116 colorectal cancer cell line, enzastaurin blocked signaling through the PKC and AKT pathways, induced apoptosis and blocked angiogenesis. The compound was more potent in GEO colon and GLC82 non small cell lung cancer (NSCLC) and less potent in MDA-468 breast, PC3 prostate and SKLU1 NSCLC cells. Enzastaurin treatment suppressed GSK3-beta phosphorylation in all cancer cell lines tested.  In cancer cells resistant to EGFR inhibitors &lt;ulink linkID="11603" linkType="Drug"&gt;gefitinib&lt;/ulink&gt;  or &lt;ulink linkID="10388" linkType="Drug"&gt;cetuximab&lt;/ulink&gt;,  enzastaurin demonstrated strong inhibitory activity, induction of apoptosis and perturbation of cell cycle distribution [&lt;ulink linkID="659906" linkType="Reference"&gt;659906&lt;/ulink&gt;], [&lt;ulink linkID="659757" linkType="Reference"&gt;659757&lt;/ulink&gt;]. Similar data were presented in  November 2006, at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague, Czech Republic [&lt;ulink linkID="742708" linkType="Reference"&gt;742708&lt;/ulink&gt;], [&lt;ulink linkID="742683" linkType="Reference"&gt;742683&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2005, at the 47th ASH meeting in Atlanta, GA, preclinical data were presented. A spectrum of multiple myeloma  cell lines were treated with Enzastaurin. There was evidence of cell death in all of these at concentrations between 1 to 3 microM after 72 h of treatment. The dexamethasone-sensitive MM1.S cell line was used to further assess the effect of enzastaurin in the presence of dexamethasone, IGF-1 and IL-6. Dexamethasone appeared to have an additive effect in the induction of apoptosis; IGF-1 decreased the effect; and IL-6 had no effect. Enzastaurin treatment also induced a decrease in GSK-3 beta and AKTSerine473 phosphorylation and significantly inhibited VEGF-induced MM cell migration on fibronectin; IGF-1-induced MM cell migration was abrogated by   enzastaurin [&lt;ulink linkID="639929" linkType="Reference"&gt;639929&lt;/ulink&gt;], [&lt;ulink linkID="640070" linkType="Reference"&gt;640070&lt;/ulink&gt;], [&lt;ulink linkID="640870" linkType="Reference"&gt;640870&lt;/ulink&gt;]. In December 2006, similar data were presented at the 48th ASH meeting in Orlando, FL [&lt;ulink linkID="747731" linkType="Reference"&gt;747731&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2005, preclinical data on enzastaurin were presented at the 17th AACR-NCI-EORTC conference in Philadelphia, PA. The compound showed synergistic antitumor effects in combination with &lt;ulink linkID="3536" linkType="Drug"&gt;pemetrexed&lt;/ulink&gt; against thyroid cancer lines including B-CPAP, ONCO-DG-1, ML-1 and CGTH-W1 [&lt;ulink linkID="636395" linkType="Reference"&gt;636395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, preclinical data on enzastaurin were presented at the 96th AACR meeting in Anaheim, CA. Enzastaurin was shown to directly affect tumor cells, inducing apoptosis and suppressing proliferation, and GSK3-beta and ribosomal protein S6 phosphorylation. These activities were demonstrated in both cultured human cancer cell lines, in murine xenograft tumor tissues, and in peripheral blood mononuclear cells from these treated mice [&lt;ulink linkID="592297" linkType="Reference"&gt;592297&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004,  data  were presented at the 46th ASH meeting in San Diego, CA. Enzastaurin demonstrated single-agent antimyeloma activity and increased the sensitivity of multiple myeloma cells to &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; and dexamethasone [&lt;ulink linkID="574293" linkType="Reference"&gt;574293&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, preclinical data were presented at the 93rd AACR meeting in San Francisco, CA. Enzastaurin inhibited stationary human umbilical vein endothelial (HUVEC) cells to a greater extent than &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt;, paclitaxel and &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; [&lt;ulink linkID="445358" linkType="reference"&gt;445358&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2001, preclinical data were presented at the International Congress of Chemotherapy in Amsterdam, The Netherlands. Enzastaurin was assessed in a number of cell culture studies as a single agent and in combination regimens as well as in in vivo models of brain, breast, ovarian, gastric, non small-cell lung cancer, small-cell lung cancer, gastric, hepatocellular, colon and renal cell cancer. In all the models enzastaurin was shown to be effective as a single agent and/or in combination. The compound inhibited angiogenesis and decreased the number of intratumoral vessels [&lt;ulink linkID="419992" linkType="reference"&gt;419992&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2001, data were presented at the 92nd AACR meeting in New Orleans, LA. Enzastaurin was shown to be a more potent inhibitor of VEGF-stimulated HUVEC proliferation (IC50 = 150 nM, 72 h) than of human SW2 SCLC proliferation (IC50 = 3.5 microM, 72 h). The compound decreased VEGF and bFGF-induced neoangiogenesis in the rat corneal micropocket. When administered orally to mice bearing SW2 SLC or T98G glioblastoma multiforme xenografts it decreased intratumoral vessels in a dose-dependent manner [&lt;ulink linkID="404121" linkType="reference"&gt;404121&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Lilly holds exclusive worldwide rights.&lt;/para&gt;&lt;para&gt;The EMA PDCO has agreed the pediatric investigation plan (PIP) for enzastaurin for Burkitt lymphoma     [&lt;ulink linkID="1357990" linkType="Reference"&gt;1357990&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1076271">Denovo Biopharma LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2014-09-16T00:00:00.000Z</StatusDate><Source id="1594312" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1076271">Denovo Biopharma LLC</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-03-20T00:00:00.000Z</StatusDate><Source id="2018369" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-03-31T00:00:00.000Z</StatusDate><Source id="807940" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1076271">Denovo Biopharma LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-12-14T00:00:00.000Z</StatusDate><Source id="2105561" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2454">Glioblastoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="54">Carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3083">Peritoneal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1745">Follicle center lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="311">T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1264">Macroglobulinemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1264">Macroglobulinemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1745">Follicle center lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="311">T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="311">T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3083">Peritoneal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-02-09T00:00:00.000Z</StatusDate><Source id="583964" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="807789" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-20T00:00:00.000Z</StatusDate><Source id="1146873" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-20T00:00:00.000Z</StatusDate><Source id="1146873" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-03-20T00:00:00.000Z</StatusDate><Source id="1146919" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-20T00:00:00.000Z</StatusDate><Source id="801510" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-10-23T00:00:00.000Z</StatusDate><Source id="952171" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-08-31T00:00:00.000Z</StatusDate><Source id="866836" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-11-30T00:00:00.000Z</StatusDate><Source id="769265" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-11-30T00:00:00.000Z</StatusDate><Source id="1146798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-11-30T00:00:00.000Z</StatusDate><Source id="1146798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-06-30T00:00:00.000Z</StatusDate><Source id="1146879" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-11-30T00:00:00.000Z</StatusDate><Source id="846863" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-11-30T00:00:00.000Z</StatusDate><Source id="846863" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-11-30T00:00:00.000Z</StatusDate><Source id="846863" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-11-30T00:00:00.000Z</StatusDate><Source id="846863" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-09-24T00:00:00.000Z</StatusDate><Source id="1216138" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-16T00:00:00.000Z</StatusDate><Source id="1146924" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-16T00:00:00.000Z</StatusDate><Source id="1146924" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-02-29T00:00:00.000Z</StatusDate><Source id="1146811" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1264">Macroglobulinemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-07-09T00:00:00.000Z</StatusDate><Source id="1069509" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-07-09T00:00:00.000Z</StatusDate><Source id="1069509" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-07-09T00:00:00.000Z</StatusDate><Source id="1069509" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-11-30T00:00:00.000Z</StatusDate><Source id="846863" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-03-31T00:00:00.000Z</StatusDate><Source id="866843" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="54">Carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-11-30T00:00:00.000Z</StatusDate><Source id="769265" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-11-30T00:00:00.000Z</StatusDate><Source id="769265" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-11-30T00:00:00.000Z</StatusDate><Source id="846863" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-11-30T00:00:00.000Z</StatusDate><Source id="846863" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-05-30T00:00:00.000Z</StatusDate><Source id="670272" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-03-09T00:00:00.000Z</StatusDate><Source id="654683" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-05-30T00:00:00.000Z</StatusDate><Source id="670272" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-05-30T00:00:00.000Z</StatusDate><Source id="670272" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-20T00:00:00.000Z</StatusDate><Source id="680250" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-31T00:00:00.000Z</StatusDate><Source id="670272" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-20T00:00:00.000Z</StatusDate><Source id="680250" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-20T00:00:00.000Z</StatusDate><Source id="680250" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-20T00:00:00.000Z</StatusDate><Source id="680250" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-20T00:00:00.000Z</StatusDate><Source id="680250" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-20T00:00:00.000Z</StatusDate><Source id="680250" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-11-30T00:00:00.000Z</StatusDate><Source id="846863" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-10T00:00:00.000Z</StatusDate><Source id="1418619" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1076271">Denovo Biopharma LLC</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-01-26T00:00:00.000Z</StatusDate><Source id="1889494" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-04-04T00:00:00.000Z</StatusDate><Source id="404119" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1108">Glioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-06-05T00:00:00.000Z</StatusDate><Source id="541026" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-07-02T00:00:00.000Z</StatusDate><Source id="501382" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-10-31T00:00:00.000Z</StatusDate><Source id="824510" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-08-31T00:00:00.000Z</StatusDate><Source id="866836" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-28T00:00:00.000Z</StatusDate><Source id="429846" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1076271">Denovo Biopharma LLC</OwnerCompany><Country id="US">US</Country><Indication id="1749">Diffuse large B-cell lymphoma</Indication><AwardedIndication>Treatment of diffuse large B-cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-03-04T00:00:00.000Z</MileStoneDate><Source id="1010689" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1076271">Denovo Biopharma LLC</OwnerCompany><Country id="EU">EU</Country><Indication id="1749">Diffuse large B-cell lymphoma</Indication><AwardedIndication>Treatment of diffuse large B cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-03-20T00:00:00.000Z</MileStoneDate><Source id="777813" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1076271">Denovo Biopharma LLC</OwnerCompany><Country id="EU">EU</Country><Indication id="1749">Diffuse large B-cell lymphoma</Indication><AwardedIndication>Treatment of diffuse large B cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-02-07T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1076271">Denovo Biopharma LLC</OwnerCompany><Country id="EU">EU</Country><Indication id="1108">Glioma</Indication><AwardedIndication>Treatment of glioma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-12-23T00:00:00.000Z</MileStoneDate><Source id="645104" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1076271">Denovo Biopharma LLC</OwnerCompany><Country id="EU">EU</Country><Indication id="1108">Glioma</Indication><AwardedIndication>Treatment of glioma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-11-10T00:00:00.000Z</MileStoneDate><Source id="634918" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1076271">Denovo Biopharma LLC</OwnerCompany><Country id="US">US</Country><Indication id="2454">Glioblastoma</Indication><AwardedIndication>Treatment of glioblastoma multiforme</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-09-19T00:00:00.000Z</MileStoneDate><Source id="654683" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01620"><Name>Protein kinase C beta</Name><SwissprotNumbers><Swissprot>P05126</Swissprot><Swissprot>P05771</Swissprot><Swissprot>P05772</Swissprot><Swissprot>P68403</Swissprot><Swissprot>P68404</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2165676" linkType="reference" linkID="2165676"&gt;2165676&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1076271">Denovo Biopharma LLC</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17810">Eli Lilly &amp; Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7.Cl</Smiles><Smiles>Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7</Smiles><Smiles>Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7.Cl.Cl</Smiles></StructureSmiles><Deals><Deal id="150873" title="Denovo Biopharma to acquire global rights for enzastaurin from Eli Lilly   "></Deal></Deals><PatentFamilies><PatentFamily id="1068360" number="WO-2006019851" title="Methods for diagnosing and treating diabetic microvascular complications"></PatentFamily><PatentFamily id="110487" number="US-20090069377" title="Deuterium-enriched enzastaurin"></PatentFamily><PatentFamily id="1144612" number="WO-2007033374" title="Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor"></PatentFamily><PatentFamily id="1383855" number="WO-09740842" title="Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy."></PatentFamily><PatentFamily id="1436839" number="WO-2004006928" title="Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride"></PatentFamily><PatentFamily id="1460141" number="WO-09740830" title="Therapeutic treatment for VEGF related diseases."></PatentFamily><PatentFamily id="1534973" number="WO-00202116" title="Therapeutic treatment of cancer with a protein kinase C inhibitor"></PatentFamily><PatentFamily id="1574907" number="WO-09517182" title="Protein kinase C inhibitors."></PatentFamily><PatentFamily id="1777802" number="WO-2010074936" title="Enzastaurin for the treatment of cancer"></PatentFamily><PatentFamily id="1994740" number="JP-2008007416" title="N- substituted aniline derivative, 1-substituted indole derivatives,1-(1 -pyridine-2-ylmethyl piperidine- 4 -yl) -1h- indole,"></PatentFamily><PatentFamily id="300038" number="WO-2010121175" title="Combination targeted therapy for lung cancer"></PatentFamily><PatentFamily id="4183778" number="WO-2018161081" title="Gene signatures to predict drug response in cancer"></PatentFamily><PatentFamily id="547031" number="WO-00202094" title="Use of a protein kinase C inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rush University Medical Center" id="1009311"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nippon Gosei Kagaku Kogyo KK" id="21661"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas A&amp;M University System" id="23290"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>